MS

Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Medical Devices, Health, Clinical Trials, Medical Supplies, Sale, Aortoiliac occlusive disease, DCB, Cell, Sundance, ISET, Master of Medicine, Freedom, Restenosis, Safety, PHD, Ambient occlusion, PP, MS, Pharmaceutical industry, MBBS, Anesthetic, FRACS

The session will be held on Wednesday, November 15th, at the 50th annual VEITH Symposium in New York, New York.

Key Points: 
  • The session will be held on Wednesday, November 15th, at the 50th annual VEITH Symposium in New York, New York.
  • Professor Varcoe previously presented SWING Trial 12-month data on January 18th at the 35th Annual International Symposium on Endovascular Therapy (ISET) conference.
  • Sirolimus, a potent anti-inflammatory and anti-proliferative compound, has been used successfully in coronary drug-eluting stents.
  • The Sundance Sirolimus Drug-Coated Balloon is not available for sale anywhere in the world, and currently is for investigational use only.

Clearway Health Expands Leadership Team with Robert Voreyer as Chief Financial Officer

Retrieved on: 
Tuesday, November 7, 2023
Health, MBA, Aetion, Growth, COVID, Hospital, CFO, Agriculture, MS, Management

BOSTON, Nov. 7, 2023 /PRNewswire/ -- Robert Voreyer, MBA, has been named chief financial officer of Clearway Health , a specialty pharmacy accelerator partnering with hospitals and health systems to build and strengthen medication access.

Key Points: 
  • BOSTON, Nov. 7, 2023 /PRNewswire/ -- Robert Voreyer, MBA, has been named chief financial officer of Clearway Health , a specialty pharmacy accelerator partnering with hospitals and health systems to build and strengthen medication access.
  • Robert Voreyer, MBA, has been named chief financial officer of Clearway Health, a specialty pharmacy accelerator.
  • "Clearway Health's substantial growth, commitment to enhancing access to lifesaving medications and joining such a high-caliber team committed towards strengthening equitable and quality care for all, are what drew me to this company," said Voreyer.
  • Voreyer also founded a boutique advisory firm, Spencer Holt Advisors, focused on solving financial, operational, and strategic challenges for clients in clean tech, health tech, agriculture and financial services.

EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts

Retrieved on: 
Tuesday, November 7, 2023
Patent, Food, Biotechnology, Multiple sclerosis, United States Patent and Trademark Office, MS, Lead, RMS, Patient, Calcium, Pharmaceutical industry, Short course immune induction therapy

The claims are expected to provide protection into 2041, unless extended further.

Key Points: 
  • The claims are expected to provide protection into 2041, unless extended further.
  • “Importantly, this patent for the dose strength in RMS patients covers all salt and free acid forms of vidofludimus calcium.
  • In the United States, these patents provide protection into 2041, unless extended further.
  • On top of the patent exclusivity, vidofludimus calcium, as a new chemical entity, should also benefit from regulatory data protection.

EQS-News: Dr. Björn Beckmann Appointed Head of Quality Control at Rentschler Biopharma’s Laupheim Site

Retrieved on: 
Tuesday, November 7, 2023
Applied science, Therapy, Quality control, CDMO, Doctor of Philosophy, DSP, Senior, Vorarlberg University of Applied Sciences, University, Site, Patient, MS, Nursing

Laupheim, Germany, October 31, 2023 – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that Dr. Björn Beckmann has been promoted to Head of Quality Control for the Company’s site in Laupheim, Germany, effective October 1, 2023.

Key Points: 
  • Laupheim, Germany, October 31, 2023 – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that Dr. Björn Beckmann has been promoted to Head of Quality Control for the Company’s site in Laupheim, Germany, effective October 1, 2023.
  • He also oversees the teams responsible for developing quality management strategies and preparing quality control audits by authorities and clients.
  • I am pleased to take on the role of Head of Quality Control in Laupheim, and I am grateful for the trust that both management and Site Head have placed in me.
  • I am extremely proud to be a part of this global, dedicated team and look forward to working together with our partners to not only meet but exceed expectations," commented Dr. Björn Beckmann, Head of Quality Control.

Anavex Life Sciences Appoints Senior VP of Regulatory Affairs

Retrieved on: 
Monday, November 6, 2023
Alzheimer's disease, FDA, Therapy, Medicine, Health Canada, Psychiatry, Rutgers University, Doctor of Philosophy, CNS, Senior, DSM-IV codes, Rett syndrome, MLS, Parkinson's disease, Central nervous system, EMA, MS, Neurology, NDA, Pharmacy, Patient, Regulatory affairs, Pharmaceutical industry, Pharmacist

Mr. Goldberger will succeed retiring Senior Vice President Regulatory Affairs, Emmanuel O Fadiran, RPh, MS, PhD.

Key Points: 
  • Mr. Goldberger will succeed retiring Senior Vice President Regulatory Affairs, Emmanuel O Fadiran, RPh, MS, PhD.
  • “We are delighted to welcome Mr. Goldberger to the Anavex team,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.
  • Prior to Otsuka he held senior level positions in Global Regulatory Affairs for Johnson and Johnson (J&J) Pharmaceutical Research and Development in Global Regulatory Affairs.
  • In addition, he led CMC Regulatory Affairs, Labeling, Regulatory Operations/Technology and Medical Writing areas.

Daré Bioscience to Participate in Three November Conferences

Retrieved on: 
Monday, November 6, 2023
Cream, Female, Bayer, Health, JD, Treatment, Medicine, Business development, Arousal, MS, SAN, Pharmaceutical industry, MD, Collaboration

The speakers will be:

Key Points: 
  • The speakers will be:
    Imran Nasrullah, MS, JD, Vice President & Head, Collaborate to Cure Hub US, Business Development & Licensing, Bayer Pharmaceuticals
    Details: A live webcast of Ms. Johnson’s presentation will be available at https://wsw.com/webcast/stifel83/dare/2064568 and under “Presentations, Events & Webcasts" in the Investors section of the company's website at https://ir.darebioscience.com .
  • The webcast will be archived in the same section of the company’s website and available for replay until November 28, 2023.
  • Ms. Johnson will also be available for one-on-one meetings at the conference.
  • Format: Abstract Presentation by Andrew T. Goldstein, MD
    Details: Dr. Goldstein will present an abstract titled “Preliminary Efficacy of Sildenafil Cream, 3.6% in an Exploratory, Randomized, Placebo-Controlled, Phase 2b Trial for the Treatment of Female Sexual Arousal Disorder.”

Study: Brain Training Improves Cognitive Function In Multiple Sclerosis

Retrieved on: 
Monday, November 6, 2023
Attention, Ageing, Medicare, SDMT, Dementia, Research, Exercise, Quality of life, Memory, Deficit spending, Posit Science Corporation, Movement, Patient, Grammatical mood, Hearing, Cognition, MS, Central nervous system, Pharmaceutical industry, Nursing

While often associated with motor control issues, MS also commonly includes cognitive and neurological challenges.

Key Points: 
  • While often associated with motor control issues, MS also commonly includes cognitive and neurological challenges.
  • Diminished speed of information processing, which can affect both movement and cognition, is one of the most common cognitive deficits .
  • These results confirm and extend findings in prior studies of cognitive training in MS, including seven prior studies using BrainHQ .
  • The study report concludes: “This study provides evidence that computerized cognitive training with BrainHQ is a valuable option for [people with MS] suffering from cognitive decline.

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Retrieved on: 
Friday, November 3, 2023
Survival, Standard of care, Society for Immunotherapy of Cancer, CADL, Injection, Doctor of Philosophy, CA19-9, Poster, CD8, Pancreatitis, SITC, B cell, Cancer, Chemoradiotherapy, Recurrence, Annual general meeting, Pancreatic cancer, SOC, Tumor microenvironment, Therapy, Patient, Toxicity, MS, Vaccine, Pharmaceutical industry, Candel, MD, Fellow of the Academy of Medical Sciences, Immunotherapy, PDAC

Data were presented today in a poster session titled ‘Neoadjuvant CAN-2409+Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC) at the 2023 Society for Immunotherapy (SITC) Annual Meeting.

Key Points: 
  • Data were presented today in a poster session titled ‘Neoadjuvant CAN-2409+Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC) at the 2023 Society for Immunotherapy (SITC) Annual Meeting.
  • “Given frequent recurrence and short survival with SoC chemotherapy for non-metastatic PDAC, effective new treatment options are urgently needed,” said Garrett Nichols, MD, MS, Chief Medical Officer of Candel.
  • “We are encouraged by the improved survival associated with CAN-2409 for the treatment of borderline resectable PDAC, demonstrated for the first time in a randomized clinical trial.
  • Only one patient randomized to control SoC chemotherapy remained alive at data cut-off (alive at 43 months).

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

Retrieved on: 
Friday, November 3, 2023
FDA, Research, Regenerative Medicine Advanced Therapy, Food, Spinal muscular atrophy, Biogen, SCD, Life, Public expenditure, TDT, Cas9, Sickle cell disease, Regulation of tobacco by the U.S. Food and Drug Administration, Poster, Society, ASH, Commercialization, HSC, File, Fetal hemoglobin, Collaboration, Lead, Beta thalassemia, Anemia, Multiple sclerosis, Bone marrow, Therapy, Patient, BLA, MS, Pharmaceutical industry, Cryptocurrency, Edith A. Perez, Editas Medicine, EU

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the third quarter 2023 and provided business updates.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the third quarter 2023 and provided business updates.
  • Cash, cash equivalents, and marketable securities as of September 30, 2023, were $446.4 million compared to $480.0 million as of June 30, 2023.
  • The increase is primarily related to an upfront payment for the non-exclusive Cas9 license to Vor Bio in the third quarter of 2023.
  • Editas Medicine plans to participate in the following scientific and medical conference:
    Editas Medicine plans to participate in the following investor events:

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

Retrieved on: 
Wednesday, November 1, 2023
Research, AD, Food, Health care, Biomarker, ATCC, Macrophage, World Intellectual Property Organization, Data, White matter, Phase, MHRA, MRI, MDS, CELL, Hereditary leiomyomatosis and renal cell cancer syndrome, Prostate cancer, Dementia, China International Search and Rescue Team, ATCC (company), Phagocytosis, EEG, Cancer, Patient, MS, BOCA, Human, Neurodegenerative disease, Conference, CTA, Patent Cooperation Treaty, AAIC, PCT, NK, Brain, Remyelination, Grey, AML, Carcinoma, FDA, IND, Medication, CNS, Treatment-resistant depression, Drug development, Pharmacotherapy, Neuroinflammation, WIPO, Cross, Cognition, Vaccine, Pharmaceutical industry, Medical imaging, Cryptocurrency, Health, Immunotherapy, Disease

BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.
  • Recruitment of the trial is increasing and the company anticipates results of the Phase II program towards the end of 2024.
  • Other expense was approximately $0.0 million for the quarter ended September 30, 2023, compared to approximately $0.3 million during the quarter ended September 30, 2022.
  • Please ask for the INmune Bio Third Quarter Conference Call when reaching an operator.